What tirzepatide is, how it works, and what the evidence shows

Where the evidence for tirzepatide began, and what it found

The clearest way to understand tirzepatide is to start with the trial that defined it. SURMOUNT-1, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and no type 2 diabetes across multiple doses. After 72 weeks, participants on the 15 mg dose lost an average of around 20–21% of their starting body weight. That figure is worth sitting with: in earlier large trials of GLP-1 medicines, average losses in the 15% range were considered landmark results. Tirzepatide's dual mechanism appears to push further, a conclusion reinforced by the SURMOUNT-5 head-to-head comparison (published in the NEJM in 2025) in which tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks.

Why the difference? Single GLP-1 receptor agonists mimic one gut hormone. Tirzepatide also activates glucose-dependent insulinotropic polypeptide (GIP) receptors, adding a second signal involved in fat storage, insulin response and, researchers believe, receptor-level sensitivity. The clinical picture is that appetite suppression is deeper and the metabolic response broader. The full overview of tirzepatide's clinical profile covers the mechanism in more detail for anyone who wants to read further.

What these trials do not tell you is whether tirzepatide is right for you. Trial populations are controlled; real-world patients bring their own medical history, other medicines and individual responses. That is precisely the assessment a prescriber makes before any prescription is written.

Who the UK licence actually covers, reading the eligibility carefully

Tirzepatide holds a UK marketing authorisation for weight management in adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, dyslipidaemia, obstructive sleep apnoea or type 2 diabetes. Lower thresholds apply for some ethnic backgrounds under UK guidance. The licence also covers type 2 diabetes management at the same doses.

NICE's appraisal (TA1026) set a higher bar for NHS funding: a BMI of 35 or above with at least one qualifying comorbidity, within a phased rollout that is currently expanding. Private eligibility, by contrast, follows the licensed indication (BMI 30-plus, or 27-plus with a relevant condition) subject to a full prescriber assessment. BMI alone never guarantees a prescription; the prescriber weighs the whole picture, including contraindications and current medicines.

If you want to compare private and NHS routes side by side, the weight-loss treatment overview sets out the practical differences clearly. For anyone already on treatment elsewhere and wondering about switching, the comparison of Mounjaro and tirzepatide naming clarifies how the two relate, the brand and the molecule are the same thing.

Side effects worth knowing about before you form an opinion

The side-effect profile of tirzepatide is dominated by gastrointestinal symptoms. Nausea, loose stools, constipation, indigestion and occasional vomiting are reported most often, typically in the weeks after starting or after a dose increase, and generally settling as the body adapts. Fatigue, headache and injection-site reactions are also noted. If you are new to this medicine and want a plain-language explanation of what it is and how it works, the tirzepatide definition page is a useful starting point before reading further. The NHS patient information page for tirzepatide on the NHS website lists these in plain language and is worth bookmarking, a quick check of that page takes under a minute and gives you a reliable reference point if anything unfamiliar comes up during treatment.

A small number of more serious effects require prompt medical attention: severe or persistent stomach pain that spreads to the back (a possible sign of pancreatitis), gallbladder symptoms, and signs of a serious allergic reaction. The medicine is not recommended during pregnancy, breastfeeding, or when actively trying to conceive. It is not licensed for under-18s. Anyone with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should discuss this with a prescriber before considering tirzepatide at all.

For anyone thinking about what treatment might cost, the Mounjaro pricing page explains what private treatment typically involves, including what a legitimate price should cover and why the lowest advertised figure is rarely the whole story.

What to check before obtaining tirzepatide privately

Tirzepatide's results have made it a target for counterfeit supply. The MHRA has warned publicly about fake weight-loss pens sold online and through social media, some containing insulin rather than the labelled medicine. In October 2025, the first UK site manufacturing counterfeit tirzepatide pens was raided in Northampton; enforcement that year seized around 20 million doses of illegally traded weight-loss medicines with an estimated street value of £45 million. The pattern is consistent: sellers offering these medicines without a prescription, prices far below the legitimate market, and no verifiable pharmacy registration.

Any legitimate online pharmacy dispensing prescription medicines in the UK must be registered with the General Pharmaceutical Council. You can verify a pharmacy in seconds at the GPhC register, search by name or registration number. The about nume page includes our GPhC premises registration number (9012878) for exactly this reason. Our prescribers are also available to answer questions through the contact page if you have specific concerns before starting a consultation. If you are comparing options across different providers or formulations, the tirzepatide options page brings together the relevant details in one place.

If you are ready to see whether tirzepatide is clinically appropriate for you, the next step is straightforward: check your eligibility through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber.